Area of Interest Biomarker Discovery Biomarker Discovery with Imaging Mass Cytometry

Biomarkery Discovery

Discovering new biomarkers using Imaging Mass Cytometry 

Biomarkers are currently used in research and in clinical practice, yet few are used to predict a clinical therapeutic outcome consistently and accurately. Particularly for cancer and other diseases with high tumor heterogeneity and broad cellular signatures, classification at an individual level is confounding. Imaging Mass Cytometry™ (IMC)™ can be used to uncover novel phenotypes and identify therapeutic targets that may be relevant to developing biomarkers and future treatment strategies.  

Blue icon illustrating biomarker discovery application

Potential indicative immunotherapy biomarker in melanoma 

Martinez-Morilla and colleagues demonstrated the use of IMC to quantitively measure 25 markers simultaneously to generate data from tumor, stroma, T cells, B cells and macrophages. Using IMC with biopsy samples from metastatic melanoma patients who received immunotherapy, the team discovered a compelling biomarker potentially indicative of treatment response in melanoma. 

Read publication

Answering key questions about the role of CAFs in lung cancer 

In her webinar, Handan Xiang, PhD, describes how she and the team at Merck use IMC studies to understand cancer-associated fibroblasts in tumor stroma. Learn how this research illuminated a possible therapeutic path that could potentially reverse a CAF-mediated immunosuppressive microenvironment.  

Watch Handan Xiang's webinar 

Novel signaling networks identified through IMC and transcriptomics data integration 

The use of IMC enabled researchers to uncover the heterogeneity of cellular phenotypes and cell-to-cell interactions in the tumor microenvironment of high-grade serous ovarian cancer to understand which interactions might influence patient survival. Learn about the pipeline used to generate PhenoGraph clusters for cell density and neighborhood analysis along with correlating the IMC phenotype with a gene expression profile. 

Read publication 

Unique expression signatures in Hodgkin lymphoma aid in the development of novel biomarkers 

Scientists aim to unravel the very complex tumor microenvironment (TME) of Hodgkin lymphoma by deciphering the unique immune cell architecture of the TME and for the first time unveil its phenotype. They pair IMC with single-cell transcriptome analysis and suggest implications for the development of novel therapies, including rational combinations and predictive biomarker development. 

Read publication 

Publications

Powering over 1,500 scientific publications with our products

VIEW ALL

Yongpan Yan, PhD

Spotlight IMC YONGPAN YAN

An approach that combines molecular biology, immunology and cell biology tools to uniquely

Febe van Maldegem, PhD, and Karishma Valand

Spotlight IMC FEBE VAN MALDEGEM, PHD, AND KARISHMA VALAND

Imaging the dramatic remodeling of the lung tumor microenvironment

Melissa Davis, PhD

Spotlight IMC MELISSA DAVIS

Defining spatial characteristics using Imaging Mass Cytometry

Customer Stories

Learn more about how our customers are leveraging Fluidigm technology.

VIEW ALL

Unless explicitly and expressly stated otherwise, all Fluidigm products are provided for Research Use Only, not for use in diagnostic procedures. For more information see www.fluidigm.com/legal/notices